Trial ID or NCT#

NCT00946673

Status

NOT RECRUITING

Purpose

The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Official Title

A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Griffith Harsh, MD
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center
Scott G. Soltys, MD
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Joel Neal, MD, PhD
Medical oncologist, Thoracic specialist
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon, Neuro-oncologist
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology-Head and Neck Surgery
Iris C. Gibbs, MD, FACR
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Heather Wakelee, MD
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061